Document Detail


Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia.
MedLine Citation:
PMID:  20685551     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preeclampsia is a common complication of pregnancy with potentially devastating consequences to both the mother and the baby.It is the leading cause of maternal deaths in developing countries. In developed countries it is the major cause of iatrogenic premature delivery and contributes significantly to increasing health care cost associated with prematurity. There is currently no known treatment for preeclampsia; ultimate treatment involves delivery of the placenta. Although there are several risk factors (such as multiple gestation or chronic hypertension), most patients present with no obvious risk factors. The molecular pathogenesis of preeclampsia is just now being elucidated. It has been proposed that abnormal placentation and an imbalance in angiogenic factors lead to the clinical findings and complications seen in preeclampsia. Preeclampsia is characterized by high levels of circulating antiangiogenic factors such as soluble fms-like tyrosine kinase-1 and soluble endoglin, which induce maternal endothelial dysfunction. These soluble factors are altered not only at the time of clinical disease but also several weeks before the onset of clinical signs and symptoms. Many methods of prediction and surveillance have been proposed to identify women who will develop preeclampsia, but studies have been inconclusive. With the recent discovery of the role of angiogenic factors in preeclampsia, novel methods of prediction and diagnosis are being developed to aid obstetricians and midwives in clinical practice. This article discusses the role of angiogenic factors in the pathogenesis, prediction, diagnosis, and possible treatment of preeclampsia.
Authors:
Michelle Silasi; Bruce Cohen; S Ananth Karumanchi; Sarosh Rana
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Obstetrics and gynecology clinics of North America     Volume:  37     ISSN:  1558-0474     ISO Abbreviation:  Obstet. Gynecol. Clin. North Am.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-08-05     Completed Date:  2010-12-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709551     Medline TA:  Obstet Gynecol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  239-53     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Kirstein 3182, Boston, MA 02215, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenic Proteins* / physiology
Female
Fetal Diseases / etiology
Humans
Neovascularization, Physiologic
Placenta / blood supply
Placenta Diseases / physiopathology
Placentation*
Pre-Eclampsia / etiology*,  physiopathology,  therapy
Pregnancy
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Grant Support
ID/Acronym/Agency:
5K12 HD001255-08/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenic Proteins; 0/Vascular Endothelial Growth Factor A; EC 2.7.10.1/Protein-Tyrosine Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sickle cell disease in pregnancy.
Next Document:  Update on gestational diabetes.